Skip to main content
. 2021 Mar 2;6(2):100065. doi: 10.1016/j.esmoop.2021.100065

Table 2.

Treatment modalities

Agent Dara/dex + additional agents (N = 7), n (%)
Proteasome inhibitora 7 (100.0)
 Bortezomib 4 (57.2)
 Carfilzomib 3 (42.9)
 Ixazomib 3 (42.9)
Immunomodulatory drugs 4 (57.1)
 Lenalidomide 1 (25.0)
 Pomalidomide 3 (75.0)
Chemotherapy 1 (14.3)
 Bendamustine 1 (100.0)
 Cyclophosphamide 1 (100.0)

Dara/dex, daratumumab and dexamethasone.

a

Several patients received more than one proteasome inhibitor.